Paul Tudor Jones’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Paul Tudor Jones’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,127	Closed	-$80K	–	1744
2016 Q3	$80K	Hold	8,127	–	–	﹤0.01%	1355
2016 Q2	$46K	Hold	8,127	–	–	﹤0.01%	1554
2016 Q1	$62K	Hold	8,127	–	–	﹤0.01%	1643
2015 Q4	$108K	Buy	8,127 +784	+11%	+$13.5K	﹤0.01%	1527
2015 Q3	$121K	Sell	7,343 -3,200	-30%	-$65.6K	﹤0.01%	1412
2015 Q2	$237K	Buy	10,543 +6,717	+176%	+$106K	0.01%	1252
2015 Q1	$37K	Hold	3,826	–	–	﹤0.01%	1410
2014 Q4	$44K	Hold	3,826	–	–	﹤0.01%	1401
2014 Q3	$44K	Sell	3,826 -1,417	-27%	-$21.6K	﹤0.01%	1308
2014 Q2	$102K	Buy	5,243 +117	+2%	+$2.06K	﹤0.01%	1100
2014 Q1	$92K	Sell	5,126 -1,524	-23%	-$25K	﹤0.01%	1130
2013 Q4	$70K	Buy	+6,650	New	+$74.3K	﹤0.01%	1221

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return

Paul Tudor Jones's CASC Position: Q4 2016 in Review

Paul Tudor Jones sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 8,127 shares — an estimated $80K sold.

Paul Tudor Jones first reported a position in CASC in Q4 2013 and held it in 12 quarters. The position peaked at $237K in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

Paul Tudor Jones reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Paul Tudor Jones sold 8,127 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $80K.
Paul Tudor Jones first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 12 quarters.
Paul Tudor Jones's Cascadian Therapeutics, Inc. position peaked at $237K in Q2 2015.
57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on Tudor Investment Corp's 13F filing for Q4 2016, filed 14 Feb 2017.